Community screening for early Alzheimer's disease signs
Part of Brain & nervous system, Mental health clinical trials.
This study screens people aged 60–80 for early signs of Alzheimer's disease in a community setting. Researchers will ask you questions and may perform brain imaging to understand who might benefit from early detection and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 80 years old
- You can communicate clearly and complete a questionnaire
- You do not have severe mental health conditions
- You do not have severe problems with vision, hearing, understanding, or mobility
- You are not currently enrolled in another health study
- You can commit to study visits and procedures, or have a legal guardian who can help
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses brain scans (MRI and EEG) to better understand Alzheimer's disease. It compares people with MCI or Alzheimer's to healthy volunteers to see how the disease affects the brain.
This study tests a new way to find early signs of memory or thinking problems in older adults. It could help identify people who might benefit from earlier support or treatment.
This study checks how age affects memory and thinking, and compares people with mild memory problems, Alzheimer’s disease types, vascular dementia, and healthy controls. You may help researchers understand brain changes using thinking tests, MRI scans, and blood or spinal fluid tests.
This study uses digital tools and blood tests to check for early signs of memory problems in healthy older adults living in the community. The goal is to find people who might be at risk for conditions like Alzheimer's disease before symptoms get worse.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
Hear when a new Cognitive Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.